Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 23Breast Neoplasms 11Prostatic Neoplasms 10Stomach Neoplasms 7Carcinoma, Hepatocellular 6Small Cell Lung Carcinoma 4Melanoma 4Lymphoma 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Multiple Pulmonary Nodules 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Disease 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Smoking Cessation 2Smoking 2Sarcopenia 2Recurrence 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Tomography, X-Ray Computed × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT04740346 2021-10-27

Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)

National Cancer Center, Korea

Phase NA Recruiting
886 enrolled
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡